Federal Circuit Denies Ariad's Request

Law360, New York (January 5, 2007, 12:00 AM EST) -- In yet another setback for Ariad Pharmaceuticals Inc., a federal appeals court has rejected the drug maker’s request to hear an early appeal of a pretrial ruling in the patent infringement suit filed by rival Amgen Inc.

With its decision, the U.S. Court of Appeals for the Federal Circuit ensured the biotech dispute will head to trial in the U.S. District Court for the District of Delaware, where Amgen sued in April to invalidate Ariad’s patent.

Amgen is seeking a declaratory judgment that Ariad’s heavily litigated...
To view the full article, register now.